MedTrace Logo

Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

NCT01514123 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2020-09-17

No results posted yet for this study

Summary

This is a non-randomized, multi-dose, first-in-human, multicenter, two arm (Arm A: VGX-100 alone; Arm B: VGX-100 co-administered with bevacizumab), open label, dose escalation study in subjects with advanced or metastatic solid tumors. The study is aimed at evaluating the safety and establishing the recommended dose of the VEGF-C human monoclonal antibody VGX-100 when administered alone or in combination with bevacizumab.

Conditions

Interventions

DRUG

VGX-100

VGX-100 will be administered by IV infusion once every week

DRUG

Bevacizumab

Bevacizumab will be administered by IV infusion once every 2 weeks

Sponsors & Collaborators

  • Circadian Technologies Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Research · Circadian Technologies

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-29
Primary Completion
2014-02-07
Completion
2017-11-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01514123 on ClinicalTrials.gov